Stock Events

Stock Events

Celcuity 

$93.64
37
-$0.01-0.01% 10:06 Today

Statistics

Day High
93.8
Day Low
93.58
52W High
151.02
52W Low
44.42
Volume
24,840
Avg. Volume
-
Mkt Cap
4.58B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.44
-1.18
-0.92
-0.65
Expected EPS
-1.395455
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-177.04MNet Income

Analyst Ratings

162.00Average Price Target
The highest estimate is 177.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CELC. It's not an investment recommendation.
Microsoft
11
MSFT
Amazon
11
AMZN
NVIDIA
10
NVDA
Apple
8
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.1B
Guardant Health operates in the liquid biopsy and cancer diagnostics sector, directly competing with Celcuity's technology for detecting and analyzing cancer.
Fulgent Genetics
FLGT
Mkt Cap510.68M
Fulgent Genetics provides comprehensive genetic testing solutions, competing with Celcuity in the precision medicine and diagnostics field.
Bionano Genomics
BNGO
Mkt Cap13.9M
Bionano Genomics competes in the genomic analysis space, offering platforms that could rival Celcuity's cellular analysis technologies.
Pacific Biosciences of California
PACB
Mkt Cap357.46M
Pacific Biosciences of California offers sequencing systems that compete in the genomics and diagnostics market, relevant to Celcuity's operations.
Illumina
ILMN
Mkt Cap28.82B
Illumina provides sequencing and array-based solutions for genetic analysis, competing with Celcuity in the genomics and diagnostics market.
Qiagen NV
QGEN
Mkt Cap8.87B
Qiagen N.V. offers sample to insight solutions that compete with Celcuity in the field of molecular diagnostics and research.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Celcuity's cellular analysis in developing treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is engaged in CRISPR/Cas9 technology, presenting potential competition in the development of genomic and cellular therapies.

About

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Show more...
CEO
Brian F. Sullivan
Employees
155
Country
United States
ISIN
US15102K1007
WKN
000A2JAAX

Listings

F
DE
7VR.F
XETRA
DE
7VR.XETRA
MU
DE
7VR.MU
XNAS
US
CELC

0 Comments

Share your thoughts

FAQ

What is Celcuity stock price today?▼
The current price of CELC is $93.64 USD — it has decreased by -0.01% in the past 24 hours. Watch Celcuity stock price performance more closely on the chart.
What is Celcuity stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Celcuity stocks are traded under the ticker CELC.
Is Celcuity stock price growing?▼
CELC stock has risen by +8.14% compared to the previous week, the month change is a +6.43% rise, over the last year Celcuity has showed a +92.02% increase.
What is Celcuity market cap?▼
Today Celcuity has the market capitalization of 4.58B
When is the next Celcuity earnings date?▼
Celcuity is going to release the next earnings report on November 18, 2026.
What were Celcuity earnings last quarter?▼
CELC earnings for the last quarter are -1.44 USD per share, whereas the estimation was -1.16 USD resulting in a -23.65% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Celcuity revenue for the last year?▼
Celcuity revenue for the last year amounts to 0 USD.
What is Celcuity net income for the last year?▼
CELC net income for the last year is -177.04M USD.
How many employees does Celcuity have?▼
As of August 20, 2026, the company has 155 employees.
In which sector is Celcuity located?▼
Celcuity operates in the Health & Wellness sector.
When did Celcuity complete a stock split?▼
Celcuity has not had any recent stock splits.
Where is Celcuity headquartered?▼
Celcuity is headquartered in MINNEAPOLIS, United States.